目的 观察紫龙金片联合多西他赛注射液和注射用奈达铂治疗局部晚期非小细胞肺癌的临床疗效。方法 选取2014年2月—2015年7月于天津市胸科医院呼吸与危重症科住院的局部晚期非小细胞肺癌确诊患者78例,随机分为对照组和治疗组,每组各39例。对照组给予多西他赛注射液75 mg/m²,溶入250 mL生理盐水,第1天静脉滴注;注射用奈达铂80 mg/m²,溶入500 mL生理盐水,第2天静脉滴注。治疗组在对照组治疗基础上口服紫龙金片2.6 g,3次/d。21 d为1个周期,患者化疗2个周期。评估肺癌患者的近期疗效,并比较患者的生活质量和T淋巴细胞亚群水平,对毒副反应进行评价。结果 化疗后对照组和治疗组的缓解率分别为15.4%、20.5%,疾病控制率分别为84.6%、92.3%,两组近期疗效比较差异无统计学意义。治疗后治疗组躯体功能、角色功能、社会功能和总健康评分较治疗前增加(P<0.05),疲倦、气促评分较治疗前下降(P<0.05);两组治疗后躯体功能、角色功能、社会功能、总健康、疲倦、气促评分比较差异均具有统计学意义(P<0.05)。治疗后,治疗组CD8显著降低,CD4/CD8显著升高,同组治疗前后差异有统计学意义(P<0.05、0.01)。治疗组CD4、CD4/CD8改善程度优于对照组,两组比较差异有统计学意义(P<0.01)。治疗组化疗所致的恶心呕吐、白细胞减少症状均轻于对照组(P<0.05)。结论 紫龙金片联合多西他赛注射液和注射用奈达铂治疗局部晚期非小细胞肺癌具有较好的临床疗效,可以改善患者的生活质量,提高患者机体免疫力,减轻化疗的毒副作用,值得在临床上进一步推广和应用。

Objective To observe the clinical curative effect of Zilongjin Tablets combined with Docetaxel Injection and Nedaplatin for injection in treatment of locally advanced non small cell lung cancer. Methods Patients (78 cases) with locally advanced non small cell lung cancer in Department of Respiration and Critical Care Medicine of Tianjin Chest Hospital from February 2014 to July 2015 were randomly divided into control and treatment groups, and each group had 39 cases. The patients in the control group were iv administered with Docetaxel Injection 75 mg/m² in the first day, added into 0.9% normal saline 250 mL. And the control group was also iv administered with Nedaplatin for injection 80 mg/m² in the second day, added into 0.9% normal saline 500 mL. The patients in the treatment group were po administered with Zilongjin Tablets 2.6 g on the basis of the control group, three times daily. A course of treatment included 3 weeks, and the patients in two groups were treated for two courses. After treatment, the efficacy was evaluated, and quality of life, levels of T lymphocyte subsets, and side effects in two groups before and after treatment were compared. Results After treatment, the remission rates in the control and treatment groups were 15.4% and 20.5%, and the control rates were 84.6% and 92.3% respectively, and there was no difference between two groups. After treatment, scores of physical function, role function, social function, and general health in treatment group were significantly increased (P < 0.05), but scores of fatigue and shortness of breath were significantly decreased (P < 0.05). After treatment, scores of physical function, role function, social function, general health, fatigue, and shortness of breath in the treatment group were better than those in the control group, with significant difference between two groups (P < 0.05). After treatment, levels of CD8 in the treatment group were obviously decreased,but CD4/CD8 was significantly increased, and the difference was statistically significant in the same group (P < 0.05, 0.01). These observational indexes in the treatment group were better than those in the control group, with significant difference between two groups (P < 0.05). Nausea and vomiting and leucopenia in treatment group were better than those in the control group (P < 0.05). Conclusion Zilongjin Tablets combined with Docetaxel Injection and Nedaplatin for injection has a clinical curative effect in the treatment of locally advanced non small cell lung cancer, and can improve quality of life, improve body immunity, and reduce side effects, which has a certain clinical application value.